Related Experiment Video
Updated: Mar 20, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry
Frank Weidemann1, Sebastian K G Maier2, Stefan Störk3
1Department of Cardiology, Innere Klinik II, Katharinen-Hospital, Unna, Germany; Department of Cardiology, Comprehensive Heart Failure Center, Würzburg, Germany.
Insights
Implantable loop recorders detect significant arrhythmias in Fabry cardiomyopathy patients missed by Holter ECGs, guiding crucial therapy changes and improving outcomes for this genetic heart condition.
Area of Science:
- Cardiology
- Genetics
- Medical Devices
Background:
- Fabry cardiomyopathy, a genetic condition, causes myocardial hypertrophy and fibrosis, increasing sudden death risk.
- Clinically relevant arrhythmias are common but often undetected by standard 24-hour Holter electrocardiograms (ECGs).
- Existing guidelines for device therapy focus on hypertrophic cardiomyopathy, not Fabry cardiomyopathy with anecdotal arrhythmia evidence.
Purpose of the Study:
- To evaluate the efficacy of implanted loop recorders for continuous heart rhythm surveillance in advanced Fabry cardiomyopathy.
- To determine the impact of detected arrhythmias on therapeutic interventions in these patients.
Main Methods:
- A prospective study involving 16 patients with advanced Fabry cardiomyopathy and hypertrophy.
- Patients received an implantable loop recorder and underwent telemedicine follow-up for a median of 1.2 years.
- The primary endpoint was a therapy-changing event detected by the loop recorder.
Main Results:
- The loop recorder detected numerous arrhythmias, including asystole, bradycardia, atrial fibrillation, and ventricular tachycardia.
- 15 of the detected events led to significant therapy changes, such as pacemaker/defibrillator implantation or anticoagulation.
- Continuous monitoring revealed clinically relevant arrhythmias often missed by Holter ECGs.
Conclusions:
- Implantable loop recorders effectively detect arrhythmias in advanced Fabry cardiomyopathy that are missed by Holter ECGs.
- Telemonitoring with these devices facilitates timely therapeutic adjustments, including device implantation and anticoagulation.
- Continuous surveillance is crucial for managing arrhythmia risk in Fabry cardiomyopathy patients.
Abstract:
Patients with genetic cardiomyopathy that involves myocardial hypertrophy often develop clinically relevant arrhythmias that increase the risk of sudden death. Consequently, guidelines for medical device therapy were established for hypertrophic cardiomyopathy, but not for conditions with only anecdotal evidence of arrhythmias, like Fabry cardiomyopathy. Patients with Fabry cardiomyopathy progressively develop myocardial fibrosis, and sudden cardiac death occurs regularly. Because 24-hour Holter electrocardiograms (ECGs) might not detect clinically important arrhythmias, we tested an implanted loop recorder for continuous heart rhythm surveillance and determined its impact on therapy. This prospective study included 16 patients (12 men) with advanced Fabry cardiomyopathy, relevant hypertrophy, and replacement fibrosis in "loco typico." No patients previously exhibited clinically relevant arrhythmias on Holter ECGs. Patients received an implantable loop recorder and were prospectively followed with telemedicine for a median of 1.2 years (range 0.3 to 2.0 years). The primary end point was a clinically meaningful event, which required a therapy change, captured with the loop recorder. Patients submitted data regularly (14 ± 11 times per month). During follow-up, 21 events were detected (including 4 asystole, i.e., ECG pauses ≥3 seconds) and 7 bradycardia events; 5 episodes of intermittent atrial fibrillation (>3 minutes) and 5 episodes of ventricular tachycardia (3 sustained and 2 nonsustained). Subsequently, as defined in the primary end point, 15 events leaded to a change of therapy. These patients required therapy with a pacemaker or cardioverter-defibrillator implantation and/or anticoagulation therapy for atrial fibrillation. In conclusion, clinically relevant arrhythmias that require further device and/or medical therapy are often missed with Holter ECGs in patients with advanced stage Fabry cardiomyopathy, but they can be detected by telemonitoring with an implantable loop recorder.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Holter Monitor: 24-Hour Monitoring
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...

